{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:56:23Z","timestamp":1778730983668,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.biochi.2022.04.005","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T01:33:32Z","timestamp":1650072812000},"page":"60-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice"],"prefix":"10.1016","volume":"199","author":[{"given":"Zara J.","family":"Franklin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan A.","family":"Lafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finbarr P.M.","family":"O'Harte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2022.04.005_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s001250100006","article-title":"Effects of a novel glucagon receptor antagonist (Bay 27\u20139955) on glucagon-stimulated glucose production in humans","volume":"44","author":"Petersen","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.biochi.2022.04.005_bib2","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/oby.2012.67","article-title":"The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin","volume":"20","author":"Kosinski","year":"2012","journal-title":"Obesity"},{"key":"10.1016\/j.biochi.2022.04.005_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.peptides.2018.04.008","article-title":"Oxyntomodulin analogue increases energy expenditure via the glucagon receptor","volume":"104","author":"Scott","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.biochi.2022.04.005_bib4","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClin. Med."},{"key":"10.1016\/j.biochi.2022.04.005_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.689678","article-title":"Proglucagon-derived peptides as therapeutics","volume":"12","author":"Lafferty","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biochi.2022.04.005_bib8","doi-asserted-by":"crossref","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","article-title":"GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet","volume":"293","author":"McClean","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"23","key":"10.1016\/j.biochi.2022.04.005_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.beem.2009.03.001","article-title":"Therapeutic potential for GIP receptor agonists and antagonists","author":"Irwin","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.biochi.2022.04.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170203","article-title":"Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes","volume":"125","author":"Irwin","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.biochi.2022.04.005_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2337\/dc19-1328","article-title":"Efficacy and safety of the glucagon receptor antagonist RVT-1502 in type 2 diabetes uncontrolled on metformin monotherapy: a 12-week dose-ranging study","volume":"43","author":"Pettus","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biochi.2022.04.005_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12020-018-1597-1","article-title":"Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Gumbiner","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.biochi.2022.04.005_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2337\/dc18-1343","article-title":"Antisense inhibition of glucagon receptor by IONIS-GCGRRx improves type 2 diabetes without increase in hepatic glycogen content in patients with type 2 diabetes on stable metformin therapy","volume":"42","author":"Morgan","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biochi.2022.04.005_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170296","article-title":"Glucagon-based therapy: past, present and future","volume":"127","author":"Patil","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.biochi.2022.04.005_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2013.03.041","article-title":"O'Harte FPM. DesHis1Glu9-glucagon-[mPEG] and desHis 1Glu9(Lys30PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity","volume":"709","author":"Irwin","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biochi.2022.04.005_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1515\/hsz-2013-0224","article-title":"Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice","volume":"395","author":"Franklin","year":"2014","journal-title":"Biol. Chem."},{"key":"10.1016\/j.biochi.2022.04.005_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.peptides.2014.08.002","article-title":"Ablation of glucagon receptor signalling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice","volume":"60","author":"McShane","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.biochi.2022.04.005_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2013.07.014","article-title":"Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists","volume":"381","author":"O'Harte","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biochi.2022.04.005_bib19","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1021\/acs.jmedchem.0c02069","article-title":"Optimization of truncated glucagon peptides to achieve selective, high potency, full antagonists","volume":"64","author":"Yang","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.biochi.2022.04.005_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1034\/j.1399-3011.2001.00880.x","article-title":"Development of potent glucagon antagonists: structure\u2212activity relationship study of glycine at position 4","volume":"58","author":"Ahn","year":"2001","journal-title":"J.\u00a0Pept. Res."},{"key":"10.1016\/j.biochi.2022.04.005_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF00573846","article-title":"Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs","volume":"44","author":"Hruby","year":"1982","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biochi.2022.04.005_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/JOE-15-0463","article-title":"Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice","volume":"229","author":"McShane","year":"2016","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.biochi.2022.04.005_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/BC.2008.019","article-title":"Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets","volume":"389","author":"Cassidy","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.biochi.2022.04.005_bib24","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00125-011-2217-2","article-title":"Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice","volume":"54","author":"Mu","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.biochi.2022.04.005_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-001025","article-title":"Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes","volume":"8","author":"Lang","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.biochi.2022.04.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170349","article-title":"Glucagon receptor antagonism promotes the production of gut proglucagon-derived peptides in diabetic mice","volume":"131","author":"Lang","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.biochi.2022.04.005_bib27","doi-asserted-by":"crossref","first-page":"12506","DOI":"10.1074\/jbc.M600127200","article-title":"Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist","volume":"281","author":"Pan","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2022.04.005_bib28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1152\/ajpendo.00102.2010","article-title":"Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor","volume":"229","author":"Gu","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biochi.2022.04.005_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129543","article-title":"Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction","volume":"1864","author":"Lafferty","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.biochi.2022.04.005_bib30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00252768","article-title":"Abnormal plasma glucose and insulin responses in heterozygous lean (ob\/+) mice","volume":"20","author":"Flatt","year":"1981","journal-title":"Diabetologia"},{"key":"10.1016\/j.biochi.2022.04.005_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4239\/wjd.v7.i17.354","article-title":"Update on the treatment of type 2 diabetes mellitus","volume":"7","author":"Mar\u00edn-Pe\u00f1alver","year":"2016","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.biochi.2022.04.005_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042784","volume":"10","author":"Angwin","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.biochi.2022.04.005_bib33","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biochi.2022.04.005_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170225","article-title":"Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates","volume":"125","author":"Knerr","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.biochi.2022.04.005_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.peptides.2017.11.021","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents","volume":"100","author":"Gasbjerg","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.biochi.2022.04.005_bib36","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys Cell","volume":"5","author":"Lu","year":"2021","journal-title":"Rep. Med."},{"key":"10.1016\/j.biochi.2022.04.005_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249239","article-title":"Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism","volume":"16","author":"West","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2022.04.005_bib38","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biochi.2022.04.005_bib39","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.bcp.2009.05.037","article-title":"Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties","volume":"78","author":"Kerr","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biochi.2022.04.005_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biochi.2022.04.005_bib41","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00125-014-3296-7","article-title":"A\u00a0novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation","volume":"57","author":"Lynch","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.biochi.2022.04.005_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.mce.2016.05.012","article-title":"Novel dual agonist peptide analogues derived from dogfish glucagon show promising in\u00a0vitro insulin releasing actions and antihyperglycaemic activity in mice","volume":"431","author":"O'Harte","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biochi.2022.04.005_bib43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1677\/JOE-06-0018","article-title":"Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes","volume":"192","author":"Claus","year":"2007","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.biochi.2022.04.005_bib44","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-64-5-896","article-title":"Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency","volume":"64","author":"Nair","year":"1987","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"issue":"24","key":"10.1016\/j.biochi.2022.04.005_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tem.2012.11.008","article-title":"Glucagon-like peptide 1 and appetite","author":"Dailey","year":"2013","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.biochi.2022.04.005_bib46","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.3389\/fncel.2019.00205","article-title":"The role of ghrelin in regulating synaptic function and plasticity of feeding-associated circuits","volume":"13","author":"Serrenh","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.biochi.2022.04.005_bib47","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"330","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.biochi.2022.04.005_bib48","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1152\/ajpendo.90281.2008","article-title":"Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity","volume":"295","author":"Copeland","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biochi.2022.04.005_bib49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.2004.059741","article-title":"Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans","volume":"55","author":"Schirra","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.biochi.2022.04.005_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjp.0705120","article-title":"Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity","volume":"138","author":"Runge","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biochi.2022.04.005_bib51","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/dc15-1643","article-title":"Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies","volume":"1241","author":"Kazda","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biochi.2022.04.005_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/JCI20911","article-title":"Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors","volume":"113","author":"Sloop","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.biochi.2022.04.005_bib53","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbrc.2019.03.148","article-title":"Glucagon receptor antagonism increases mouse pancreatic \u03b4-cell mass through cell proliferation and duct-derived neogenesis","volume":"512","author":"Gu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biochi.2022.04.005_bib54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/db18-1293","article-title":"Glucagon receptor antagonist-stimulated \u03b1-cell proliferation is severely restricted with advanced age","volume":"68","author":"Lam","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.biochi.2022.04.005_bib55","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1073\/pnas.1621069114","article-title":"Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice","volume":"114","author":"Okamoto","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biochi.2022.04.005_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.633625","article-title":"Positive effects of NPY1 receptor activation on islet structure are driven by pancreatic alpha- and beta-cell transdifferentiation in diabetic mice","volume":"12","author":"Lafferty","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biochi.2022.04.005_bib57","article-title":"Glucagon blockade restores functional \u03b2-cell mass in type 1 diabetic mice and enhances function of human islets","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biochi.2022.04.005_bib58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13543776.2020.1769600","article-title":"Small molecule glucagon receptor antagonists: an updated patent review (2015-2019)","volume":"30","author":"Cheng","year":"2020","journal-title":"Expert Opin. Ther. Pat."}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908422001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908422001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:21:52Z","timestamp":1759540912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908422001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":56,"alternative-id":["S0300908422001006"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2022.04.005","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2022.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}